Location History:
- Decatur, GA (US) (2016 - 2018)
- Cincinnati, OH (US) (2018 - 2020)
- Memphis, TN (US) (2021)
Company Filing History:
Years Active: 2016-2021
Title: Jianxiong Jiang: Innovator in Prostaglandin Receptor Research
Introduction
Jianxiong Jiang is a prominent inventor based in Cincinnati, OH (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of Prostaglandin receptor EP2 antagonists. With a total of 5 patents to his name, Jiang's work has the potential to impact various medical conditions.
Latest Patents
Jiang's latest patents focus on Prostaglandin receptor EP2 antagonists, derivatives, compositions, and their related uses. The disclosures detail methods for treating or preventing conditions where EP2 receptor activation plays a physiological role. These conditions include brain injury, inflammatory diseases, neuroinflammation after seizures, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders. The pharmaceutical compositions developed by Jiang aim to provide therapeutic benefits to subjects in need.
Career Highlights
Jiang is currently affiliated with Emory University, where he continues to advance his research in pharmacology and drug development. His innovative approaches have garnered attention in the scientific community, contributing to the understanding of Prostaglandin receptors and their implications in various diseases.
Collaborations
Throughout his career, Jiang has collaborated with notable colleagues, including Thota Ganesh and Ray J Dingledine. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of their research.
Conclusion
Jianxiong Jiang is a dedicated inventor whose work on Prostaglandin receptor EP2 antagonists holds promise for treating a range of medical conditions. His contributions to the field of pharmaceutical sciences are noteworthy and continue to inspire further research and innovation.